natgillin/translations-raw huggingface dataset:
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Laventair’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Laventair večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Lenvima’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Lenvima večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Lixiana’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Lixiana večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Lojuxta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Lojuxta večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Lonsurf’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Lonsurf večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Lynparza’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Lynparza večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Mekinist’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Mekinist večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Mirvaso’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Mirvaso večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Moventig’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Moventig večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Neuraceq’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Neuraceq večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Nexium Control’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Nexium Control večje od z njim povezanih tveganj, in priporočil, da se zdravilo odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Nivolumab BMS’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Nivolumab BM večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that NovoEight’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila NovoEight večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that NovoRapid’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila NovoRapid večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Nucala’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Nucala večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Nuedexta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Nuedexta večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Nuwiq’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Nuwiq večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Odomzo’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Odomzo večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ofev’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Ofev večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Olysio’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Olysio večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ongentys’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Ongentys večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Onivyde’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Onivyde večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Opdivo’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Opdivo večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Orbactiv’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Orbactiv večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Orkambi’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Orkambi večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Otezla’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Otezla večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Praluent’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Praluent večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Procysbi’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Procysbi večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Provenge’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Provenge večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Qtern’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Qtern večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Quinsair’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Quinsair večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Raplixa’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Raplixa večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Relvar Ellipta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Relvar Ellipta večje od z njim povezanih tveganj, in priporočil, da se zdravilo odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Repatha’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Repatha večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Revatio’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Revatio večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Revinty Ellipta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Revinty Ellipta večje od z njim povezanih tveganj, in priporočil, da se zdravilo odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Rezolsta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Rezolsta večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ristempa’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Ristempa večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Rixubis’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Rixubis večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Saxenda’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Saxenda večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Scenesse’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Scenesse večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Senshio’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Senshio večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Sevelamer carbonate Zentiva’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Sevelamer carbonate Zentiva večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Sirturo’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Sirturo večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Sivextro’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Sivextro večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Somatropin Biopartners’ benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) agencije je zaključil, da so koristi zdravila Somatropin Biopartners večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Sovaldi’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Sovaldi večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Stayveer’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP), ki deluje v okviru agencije, je zaključil, da so koristi zdravila Stayveer večje od z njim povezanih tveganj, in priporočil, da se zdravilo odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Stelara’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Stelara večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Stivarga’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Stivarga večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Strensiq’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Strensiq večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Stribild’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Stribild večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Strimvelis’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Strimvelis večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Sylvant’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Sylvant večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Synjardy’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Synjardy večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Tafinlar’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Tafinlar večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Tagrisso’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Tagrisso večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Taltz’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Taltz večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the approved doses of Envarsus have been shown to have a comparable quality, safety and effectiveness to Advagraf and Prograf.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo dokazano, da so odobreni odmerki zdravila Envarsus po kakovosti, varnosti in učinkovitosti primerljivi z zdraviloma Advagraf in Prograf.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Coagadex are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Coagadex večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Giotrif outweigh its risks and recommended that it be granted marketing authorisation in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Giotrif večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Inductos are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Inductos večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Neparvis are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Neparvis večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Obizur are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Obizur večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Omidria are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Omidria večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.